Cell Cycle Checkpoint Therapies: Going After CDK2, ATR

CDK2 inhibitors have received some attention at the 2024 ESMO Congress, with one candidate, PF-07104091, showing combination potential with CDK4-selective blockade in HR–positive, HER2–negative breast cancer, and another, INCB123667, looking active in ovarian cancer. When it comes to inhibiting ATR, a retrospective analysis points toward the allelic status of ATM LOF tumors as a biomarker that could predict which patients are likely to benefit.